BioSpace News Archive

Union Bridge Holdings Limited announced that its subsidiary, Phoenix Creation Global Limited (“Phoenix”), has entered into a Letter of Intent with Shenyang Shenhe Yixi Home Care Service Center.

McKesson Corporation (NYSE: MCK) today announced that its Board of Directors has elected Brad Lerman as a new independent director, effective April 24, 2018. With the election of Mr. Lerman, the size of McKesson’s Board of Directors increases from eight to nine members, eight of whom are independent.

Florida Atlantic University and Max Planck Florida Institute for Neuroscience (MPFI) have combined forces to form the first jointly supported position between the two institutions.

Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) today announced it has been forced to destroy the bacterial seeds intended for use in the production of its 23-valent pneumococcal polysaccharide vaccine, or PPV, and to suspend all preparations for and ultimately postpone the China Food and Drug Administration (CFDA) inspection of the manufacturing site necessary for 23-valent PPV production approval

MJ Lifestyle, will make its official in-print and digital debut on May 4, 2018.

[30-April-2018] JERUSALEM, April 30, 2018 /PRNewswire/ -- RenalSense(R) has entered into an agreement with Fresenius Medical Care (Bad Homburg) for distribution of its Clarity RMS(R) critical care urine monitoring system in Europe, the Middle East, and Africa (EMEA). Fresenius Medical Care will market the company’s products in 85 EMEA countries through its acute care div

Spheryx, Inc. will be demonstrating their instrument, xSight, which is based on their proprietary technology, Total Holographic Characterization®, at PEGS Boston from May 1-3, 2018 in the Exhibit Hall at the Seaport World Trade Center.

MYM Nutraceuticals Inc. is pleased to announce the following key new hires bolstering its operations in Canada and around the world.

NanoSphere Health Sciences INC announced the latest addition to its cannabis product line-up using NanoSphere Health’s patented delivery technology.

ProLon® is now available in twelve countries around the world including the UK, Italy, Germany, Spain, Austria, Denmark, Finland, Iceland, Norway, Sweden, Poland, and the Philippines.